A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector

PloS One
Hirotaka EbinaYoshio Koyanagi

Abstract

DNA-editing technology has made it possible to rewrite genetic information in living cells. Human immunodeficiency virus (HIV) provirus, an integrated form of viral complementary DNA in host chromosomes, could be a potential target for this technology. We recently reported that HIV proviral DNA could be excised from the chromosomal DNA of HIV-based lentiviral DNA-transduced T cells after multiple introductions of a clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 endonuclease system targeting HIV long terminal repeats (LTR). Here, we generated a more efficient strategy that enables the excision of HIV proviral DNA using customized transcription activator-like effector nucleases (TALENs) targeting the same HIV LTR site. A single transfection of TALEN-encoding mRNA, prepared from in vitro transcription, resulted in more than 80% of lentiviral vector DNA being successfully removed from the T cell lines. Furthermore, we developed a lentiviral vector system that takes advantage of the efficient proviral excision with TALENs and permits the simple selection of gene-transduced and excised cells in T cell lines.

References

Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·T M FolksA S Fauci
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·L NaldiniI M Verma
Sep 12, 1998·Journal of Virology·H MiyoshiI M Verma
Aug 31, 2002·Cell·Astrid R W SchröderFrederic Bushman
Oct 8, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard MitchellFrederic Bushman
Feb 29, 2008·Biotechnology and Bioengineering·W T GodbeyFengqi Chang
Feb 14, 2009·The New England Journal of Medicine·Gero HütterEckhard Thiel
Nov 26, 2009·Science·Matthew J Moscou, Adam J Bogdanove
Mar 17, 2010·Cell Host & Microbe·KyeongEun LeeVineet N KewalRamani
Aug 19, 2010·Nature Reviews. Genetics·Fyodor D UrnovPhilip D Gregory
Jan 26, 2011·Proceedings of the National Academy of Sciences of the United States of America·Magdy M MahfouzJian-Kang Zhu
Aug 5, 2011·Nucleic Acids Research·Claudio MussolinoToni Cathomen
Aug 9, 2011·Nature Biotechnology·Peng HuangBo Zhang
Jan 10, 2012·Cold Spring Harbor Perspectives in Medicine·Robert F Siliciano, Warner C Greene
Jul 5, 2012·Cold Spring Harbor Perspectives in Medicine·Robert Craigie, Frederic D Bushman
Sep 25, 2012·Immunity·Evelyn Eisele, Robert F Siliciano
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jan 11, 2013·Nature Biotechnology·Young Hoon SungHan-Woong Lee
Apr 3, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark J OsbornJakub Tolar
May 15, 2013·Trends in Biotechnology·Thomas GajCarlos F Barbas
Jun 25, 2013·Nature Biotechnology·Yanfang FuJeffry D Sander
Aug 14, 2013·Nucleic Acids Research·Thomas J CradickGang Bao
Aug 27, 2013·Scientific Reports·Hirotaka EbinaYoshio Koyanagi
Oct 1, 2013·Nature Methods·Prashant MaliGeorge M Church
Oct 26, 2013·Nature Protocols·F Ann RanFeng Zhang
Nov 30, 2013·Scientific Reports·Tetsushi SakumaTakashi Yamamoto
Mar 4, 2014·Nature Biotechnology·Jeffry D Sander, J Keith Joung
Mar 7, 2014·The New England Journal of Medicine·Pablo TebasCarl H June

❮ Previous
Next ❯

Citations

Jan 1, 2016·Antiviral Research·Harshana S De Silva FeelixgeKeith R Jerome
Apr 8, 2016·Nature Biotechnology·Michelle Kim, Robert F Siliciano
Apr 20, 2016·The Journal of Antimicrobial Chemotherapy·Pavitra RoychoudhuryJoshua T Schiffer
Jun 4, 2016·BioResearch Open Access·Takenobu NiiKenzaburo Tani
May 14, 2016·Human Genetics·Ronald BenjaminMartin R Schiller
Nov 18, 2016·AIDS Patient Care and STDs·Keith R Jerome
Nov 18, 2016·AIDS Patient Care and STDs·Cathy X Wang, Paula M Cannon
Nov 15, 2016·Scientific Reports·Yi-Ying ChouTom Kirchhausen
Jul 12, 2017·Expert Review of Anti-infective Therapy·Jon HuygheLinos Vandekerckhove
Nov 2, 2017·Scientific Reports·Will DampierBrian Wigdahl
Apr 8, 2016·Blood·Cathy X Wang, Paula M Cannon
Jul 4, 2018·AIDS Research and Human Retroviruses·Will DampierBrian Wigdahl
Jun 5, 2019·Pharmaceutics·Nejat Düzgüneş, Krystyna Konopka
Apr 1, 2016·Current Opinion in HIV and AIDS·Chelsea SpraggKeith R Jerome
May 26, 2016·FEBS Letters·Bojana Lucic, Marina Lusic
Jun 10, 2016·Microbiology and Immunology·Shuhei UedaYoshio Koyanagi
Feb 18, 2017·Cellular and Molecular Life Sciences : CMLS·Kamel KhaliliJeffrey M Jacobson
Jun 10, 2017·Current Stem Cell Reports·Juliette M K M Delhove, Waseem Qasim
Jan 9, 2019·Frontiers in Microbiology·Amanda R PanfilKristine E Yoder
Dec 23, 2020·Human Gene Therapy·Tatjana I CornuToni Cathomen
Sep 2, 2019·Current Opinion in Virology·Alex OlsonAndrew J Henderson
May 31, 2019·Emerging Topics in Life Sciences·Roland Preece, Christos Georgiadis

❮ Previous
Next ❯

Methods Mentioned

BETA
Transfection
in vitro transcription
enzyme-linked immunosorbent assay
PCR
flow cytometry
ELISA
gene knockouts

Software Mentioned

CellQuest
TALEN
FlowJo
TALENs
Neon
TAL Effector Nucleotide Targeter
Platinum

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Biophysics of CRISPR

This feed focuses on broad characteristics of the CRISPR system and the proteins associated with it.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Virology & CRISPR

This feed focuses on the virology of CRISPR and its use in developing CRISPR-Cas systems. Discover the latest research here.